Superbioavailable Itraconazole 130mg versus Itraconazole 200mg in extensive dermatophytosis.

Comparison of efficacy of Superbioavailable Itraconazole 130mg versus Itraconazole 200mg in extensive dermatophytosis:Single blind, Randomized Controlled Study - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/08/072159

Enrollment

Registered

2024-08-08

Start date

Unknown

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B354- Tinea corporis

Interventions

Intervention1: Capsule Itraconazole SB 130mg: Capsule Itraconazole SB 130mg once a day for 4 weeks. Control Intervention1: Capsule Itraconazole 200mg: Capsule Itraconazole 200mg once a day for 4 weeks

Eligibility

Inclusion criteria

Inclusion criteria: Patients of age above 18 years having extensive dermatophytosis (Body surface area involvement more than 10 percentage)

Exclusion criteria

Exclusion criteria: Patient on topical antifungal therapy (15 days before study). Pregnancy. Patient having Tinea unguium, Tinea capitis infection. Patient living with HIV, diabetes mellitus. Patients on systemic immunosuppressive therapy. Patients missing follow up for more than a month. Patients not willing to participate in the study.

Design outcomes

Primary

Measure	Time frame
To compare the efficacy of ITRACONAZOLE SB 130 versus ITRACONAZOLE 200 in Extensive dermatophytosis. Timepoint: Baseline,2 weeks,4 weeks	—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactShani Jay Jayantilal

Mahatma gandhi medical college and research institute

surya.0904@gmail.com6353465891

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026